drugset / Trial / NCT05991232

Repeated Neurocognitive Measurements in Depressed Patients

NCT05991232

Phase 1/2 Withdrawn Jay Fournier
NaSingle-groupOpen-labelBasic science

Summary

In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning, and C) in a subset of the sample, determine how the functioning in those targets is altered by a single dose of ketamine.

Timeline

Start
2025-05-01
Primary completion
2028-04
Completion
2029-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intravenous

Indications